Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Bruker launches NMR-based long COVID test

August 2022—Bruker Corp. has launched PhenoRisk PACS RuO, a research use only nuclear magnetic resonance test for molecular phenomics research on blood samples of patients with post-acute COVID syndrome (PACS), or long COVID. The test uses a multiplexed combination of biomarkers and is for research on early-stage risk factors on longitudinal recovery monitoring and on potential secondary organ damage in cardiovascular disease, type 2 diabetes, kidney dysfunction, and inflammation. It runs on the Avance IVDr NMR spectroscopy system, which produces results in 20 minutes.

CSF false-bottom tube

August 2022—Sarstedt announced the availability of a false-bottom tube for cerebrospinal fluid with an elevated conical base. The tube was developed and validated for Roche, specifically for use with Roche’s new generation of Elecsys immunoassays designed to detect Alzheimer’s disease biomarkers on Cobas e analyzers. The tubes are manufactured from medical-grade polypropylene and have HDPE screw caps that are leak resistant at 95 kilopascals.

EKF to distribute FDA-cleared Lucica glycated albumin test

July 2022—EKF Diagnostics announced the availability of the FDA-cleared Lucica Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corp. and sold exclusively in the United States by EKF. Lucica Glycated Albumin-L is a specific, quantitative test for glycated albumin for the intermediate-term monitoring of glycemic control in patients with diabetes.

PerkinElmer launches BioQule NGS system

July 2022—PerkinElmer has launched its research use only BioQule NGS system, an automated benchtop solution for next-generation sequencing library preparation of up to eight samples. The system requires as little as 10 ng of starting material per run to create libraries. By incorporating automated thermocycling, integrated quality control through optical quantification, and robust liquid-handling technology in a single device, the company says the system enables researchers to produce high-quality NGS libraries that yield reliable, reproducible results.

Sarstedt launches web shop

July 2022—Sarstedt has launched a web shop for direct online ordering of its labware consumables, specimen collection devices, and small instruments. The shop is available to customers in the United States and can be accessed via the company website at www.sarstedt.com or directly at www.shop.sarstedt.us.

Seegene develops assay to detect monkeypox virus

July 2022—Seegene has developed a PCR test to detect monkeypox virus. The Novaplex MPXV assay, for research use only, was developed using the company’s AI-based automated test development system and can identify positive cases of the monkeypox virus in 90 minutes.

Steripath use studied hospitalwide

July 2022—Magnolia Medical Technologies, developers of the FDA 510(k)-cleared Steripath platform for reducing blood culture contamination for sepsis testing accuracy, announced the publication of results from a study performed by United Hospital Center, a member of the West Virginia University Health System.

BioMérieux Chikungunya dx tests get CE mark

July 2022—BioMérieux announced the CE marking of its Vidas Anti-Chikungunya IgM and Anti-Chikungunya IgG tests to diagnose Chikungunya virus infection. The tests can detect infection during the acute phase and into the chronic phase and run on the company’s Vidas immunoassay instruments.

MARKETPLACE

TRENDING